A positive view on a negative trial with DOAC after TAVR - PACE-CME

A positive view on a negative trial with DOAC after TAVR

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

A first clinical trial testing the use of an H₂S donor after heart attack
A first clinical trial testing the use of an H₂S donor after heart attack
ACC.22
A first clinical trial testing the use of an H₂S donor after heart attack
- Marie-Sophie de Koning, MD
Beginning of an era: Treatment of elevated Lp(a)
Beginning of an era: Treatment of elevated Lp(a)
ACC.22
Beginning of an era: Treatment of elevated Lp(a)
- Steven Nissen, MD
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
ACC.22
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
- Brian Bergmark, MD
PCSK9i reduces plaque burden in coronary arteries
PCSK9i reduces plaque burden in coronary arteries
ACC.22
PCSK9i reduces plaque burden in coronary arteries
- Prof. Lorenz Räber, MD, PhD